What the FDA labels say about taking them together
Pimozide and posaconazole
Posaconazole's FDA label of August 3, 2026 names pimozide in its contraindications section; pimozide's label does not name posaconazole itself but warns about its class (Azole antifungals). The posaconazole label: “Noxafil increases concentrations and toxicities of: Sirolimus CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) HMG-CoA Reductase Inhibitors …”
Check it at the source: the pimozide FDA label on DailyMed (effective August 12, 2026, Par Health USA, LLC); the posaconazole FDA label on DailyMed (effective August 3, 2026, Aurobindo Pharma Limited).
What does the pimozide label say about posaconazole?
Pimozide's label does not name posaconazole itself; it warns about its class (Azole antifungals):
Pimozide label, contraindicationsBecause azole antifungal agents are also inhibitors of the CYP 3A4 enzymes and thus may likewise impair pimozide metabolism, pimozide is contraindicated in patients receiving the azole antifungal agents itraconazole and ketoconazole.
Pimozide label, drug interactionsSince pimozide is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal agents and protease inhibitor drugs (see CONTRAINDICATIONS ).
Source: FDA drug label (Pimozide), Par Health USA, LLC, effective August 12, 2026 (SPL set 70b079e2-a1f7-4a93-8685-d60a4d7c1280), via openFDA; the full label on DailyMed
What does the posaconazole label say about pimozide?
Posaconazole label, contraindicationsSirolimus ( 4.2 , 7.2 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) Ergot alkaloids ( 4.5 , 7.2 ) Venetoclax:
Posaconazole label, drug interactionsMechanism and Clinical Effect (s); Concomitant use of posaconazole with CYP3A4 substrates such as pimozide and quinidine may result in increased plasma concentrations of the CYP3A4 substrates leading to QTc interval prolongation and torsades de pointes [see ].
Source: FDA drug label (Noxafil, NDA022003), Merck Sharp & Dohme LLC, effective February 13, 2026 (SPL set b073b082-7b57-4423-8c06-4fd4263d6f84), via openFDA
Source: FDA drug label (POSACONAZOLE), Aurobindo Pharma Limited, effective August 3, 2026 (SPL set f8a26673-261c-4e8e-b1e1-9e23aaf7f285), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pimozide | Posaconazole | |
|---|---|---|
| Labeled for | n/a | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.23 per tablet 1 mg tablet | $2.03 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once